FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2740628965> ?p ?o ?g. }

• W2740628965 endingPage "5570" @default.
• W2740628965 startingPage "5570" @default.
• W2740628965 abstract "Abstract Checkpoint inhibitors have become the cornerstone for new innovation in immune-based oncology therapy. Several orthogonal immune pathways are currently being investigated to relieve suppression or boost activity of the innate and adaptive immune system. The IDO immune-metabolism pathway was recently clinically validated in melanoma in combination with checkpoint inhibition. This opens up a new approach to relieving suppressive mediators and lends credence to the tumor microenvironment containing small molecule metabolites that induce immune tolerance. Both indoleamine-pyrrole 2,3-dioxygenase 1 (IDO1) and Tryptophan 2,3-dioxygenase (TDO) enzymes metabolize tryptophan, forming Kynurenine which binds the aryl hydrocarbon receptor (AHR) in multiple innate and adaptive immune cell types causing a net immunosuppressive effect. Both enzymes are upregulated across many tumor types, however, only the IDO1 enzyme has thus far been addressed in the clinic with small molecule inhibitors. We have postulated that enzyme-mediated depletion of Kynurenine into safe and immunologically inert metabolites can alleviate tumor immunosuppression. We have cloned and characterized several bacterial Kynureninases (KYNase) which preferentially degrade Kynurenine with a &gt;1,000 higher kcat/KM as opposed to mammalian enzymes that cleave 3-OH Kynurenine. We show that PEGylated bacterial KYNases can deplete Kynurenine produced by IDO1+, TDO+ and IDO1/TDO+ dual positive human cancer cells whereas, the IDO1 inhibitor epacadostat or TDO inhibitor 680C91 only selectively inhibited Kyn production in IDO1+ or TDO+ cells respectively. In vivo, a single subcutaneous dose of KYNase in B16F10 tumor-bearing mice was able to deplete Kynurenine in both the plasma and tumors and increase effector T-cells in the tumor. KYNase demonstrated significant tumor growth inhibition and survival benefit either as a single agent or in combination with checkpoint inhibitors (anti-PD1 or anti-CTLA4) in B16F10, CT26 and 4T1 models. Interestingly, KYNase combined with anti-PD1, showed greater efficacy than epacadostat / anti-PD1 combination in CT26 tumor bearing mice. A pharmacologically optimized human KYNase is currently moving toward clinical development for the treatment of cancers where both IDO/TDO pathways play a significant immunosuppressive role through kynurenine production. Citation Format: Michelle Zhang, Everett Stone, Todd A. Triplett, Kendra Triplett, Candice Lamb, Christos S. Karamitros, John Blazek, George Georgiou, Mark G. Manfredi. A novel approach to targeting the IDO/TDO pathway through degradation of the immunosuppressive metabolite kynurenine [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2017; 2017 Apr 1-5; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 5570. doi:10.1158/1538-7445.AM2017-5570" @default.
• W2740628965 created "2017-08-08" @default.
• W2740628965 creator A5001282420 @default.
• W2740628965 creator A5009817418 @default.
• W2740628965 creator A5034297559 @default.
• W2740628965 creator A5044737140 @default.
• W2740628965 creator A5047788420 @default.
• W2740628965 creator A5052177571 @default.
• W2740628965 creator A5059141420 @default.
• W2740628965 creator A5078295791 @default.
• W2740628965 creator A5084490470 @default.
• W2740628965 date "2017-07-01" @default.
• W2740628965 modified "2023-10-18" @default.
• W2740628965 title "Abstract 5570: A novel approach to targeting the IDO/TDO pathway through degradation of the immunosuppressive metabolite kynurenine" @default.
• W2740628965 doi "https://doi.org/10.1158/1538-7445.am2017-5570" @default.
• W2740628965 hasPublicationYear "2017" @default.
• W2740628965 type Work @default.
• W2740628965 sameAs 2740628965 @default.
• W2740628965 citedByCount "6" @default.
• W2740628965 countsByYear W27406289652020 @default.
• W2740628965 countsByYear W27406289652021 @default.
• W2740628965 countsByYear W27406289652022 @default.
• W2740628965 countsByYear W27406289652023 @default.
• W2740628965 crossrefType "journal-article" @default.
• W2740628965 hasAuthorship W2740628965A5001282420 @default.
• W2740628965 hasAuthorship W2740628965A5009817418 @default.
• W2740628965 hasAuthorship W2740628965A5034297559 @default.
• W2740628965 hasAuthorship W2740628965A5044737140 @default.
• W2740628965 hasAuthorship W2740628965A5047788420 @default.
• W2740628965 hasAuthorship W2740628965A5052177571 @default.
• W2740628965 hasAuthorship W2740628965A5059141420 @default.
• W2740628965 hasAuthorship W2740628965A5078295791 @default.
• W2740628965 hasAuthorship W2740628965A5084490470 @default.
• W2740628965 hasConcept C104317684 @default.
• W2740628965 hasConcept C136449434 @default.
• W2740628965 hasConcept C185592680 @default.
• W2740628965 hasConcept C203014093 @default.
• W2740628965 hasConcept C2776107976 @default.
• W2740628965 hasConcept C2776706248 @default.
• W2740628965 hasConcept C2777477808 @default.
• W2740628965 hasConcept C2777503454 @default.
• W2740628965 hasConcept C2777701055 @default.
• W2740628965 hasConcept C2780674031 @default.
• W2740628965 hasConcept C2780851360 @default.
• W2740628965 hasConcept C33594762 @default.
• W2740628965 hasConcept C502942594 @default.
• W2740628965 hasConcept C515207424 @default.
• W2740628965 hasConcept C55493867 @default.
• W2740628965 hasConcept C83478079 @default.
• W2740628965 hasConcept C86339819 @default.
• W2740628965 hasConcept C86803240 @default.
• W2740628965 hasConcept C8891405 @default.
• W2740628965 hasConceptScore W2740628965C104317684 @default.
• W2740628965 hasConceptScore W2740628965C136449434 @default.
• W2740628965 hasConceptScore W2740628965C185592680 @default.
• W2740628965 hasConceptScore W2740628965C203014093 @default.
• W2740628965 hasConceptScore W2740628965C2776107976 @default.
• W2740628965 hasConceptScore W2740628965C2776706248 @default.
• W2740628965 hasConceptScore W2740628965C2777477808 @default.
• W2740628965 hasConceptScore W2740628965C2777503454 @default.
• W2740628965 hasConceptScore W2740628965C2777701055 @default.
• W2740628965 hasConceptScore W2740628965C2780674031 @default.
• W2740628965 hasConceptScore W2740628965C2780851360 @default.
• W2740628965 hasConceptScore W2740628965C33594762 @default.
• W2740628965 hasConceptScore W2740628965C502942594 @default.
• W2740628965 hasConceptScore W2740628965C515207424 @default.
• W2740628965 hasConceptScore W2740628965C55493867 @default.
• W2740628965 hasConceptScore W2740628965C83478079 @default.
• W2740628965 hasConceptScore W2740628965C86339819 @default.
• W2740628965 hasConceptScore W2740628965C86803240 @default.
• W2740628965 hasConceptScore W2740628965C8891405 @default.
• W2740628965 hasIssue "13_Supplement" @default.
• W2740628965 hasLocation W27406289651 @default.
• W2740628965 hasOpenAccess W2740628965 @default.
• W2740628965 hasPrimaryLocation W27406289651 @default.
• W2740628965 hasRelatedWork W2791825614 @default.
• W2740628965 hasRelatedWork W3038084605 @default.
• W2740628965 hasRelatedWork W3134152892 @default.
• W2740628965 hasRelatedWork W3153709335 @default.
• W2740628965 hasRelatedWork W3177607563 @default.
• W2740628965 hasRelatedWork W3217412908 @default.
• W2740628965 hasRelatedWork W4213275083 @default.
• W2740628965 hasRelatedWork W4224222365 @default.
• W2740628965 hasRelatedWork W4281389645 @default.
• W2740628965 hasRelatedWork W4285731353 @default.
• W2740628965 hasVolume "77" @default.
• W2740628965 isParatext "false" @default.
• W2740628965 isRetracted "false" @default.
• W2740628965 magId "2740628965" @default.
• W2740628965 workType "article" @default.